Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy® Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.
Wegovy® has been marketed since 22 February 2024 by Novo Nordisk Pharma in Japan. Under this agreement, Novo Nordisk Pharma will be responsible for maintenance of the marketing approval as well as manufacture and supply of the product, and Novo Nordisk Pharma and Sumitomo Pharma will be jointly committed to promoting the product to healthcare professionals. The co-promotion activities by both companies will begin in November 2025.
Novo Nordisk Pharma is supporting the long-term health of people with obesity disease by committing to obesity treatment, in line with its vision of “creating an environment where all people with obesity disease receive optimal care and support.” Sumitomo Pharma engages in the development and promotion of multiple diabetes treatments, offering promising treatment options in this area. Novo Nordisk Pharma and Sumitomo Pharma have been jointly promoting Ozempic® since July 2025, under the co-promotion agreement for the type 2 diabetes treatment Ozempic®. Building upon the strong collaborative relationship established between the two companies, through this agreement for Wegovy®, they aim to contribute to the treatment of obesity disease.
Novo Nordisk Pharma and Sumitomo Pharma will work closely together in promotional activities to ensure that Wegovy® delivers as many people with obesity disease as possible, contributing to the improvement of the disease and enhancing their quality of life.
